More about
PCSK9 Inhibitor
Clinical Guidance
Lipid Management
Treatment Approaches
PCSK9 Inhibitors
Clinical Guidance
Lipid Management
Treatment Approaches
Nonstatins- Evolving Role in ASCVD Prevention
News
June 04, 2024
2 min read
Save
Evolocumab shows particular CV benefit in those with autoimmune disease, inflammation
News
February 29, 2024
3 min read
Save
Insurers reject PCSK9 inhibitors at a higher rate vs. other cardiometabolic prescriptions
News
November 17, 2023
3 min read
Save
Novel PCSK9 inhibitor recaticimab linked to durable LDL reduction
News
November 12, 2023
3 min read
Save
Early study suggests gene editing can lower LDL cholesterol via PCSK9 inhibition
News
September 08, 2023
3 min read
Save
Lerodalcibep reduces LDL in well-treated patients with HeFH vs. placebo
Part of the Healio Network
PCSK9 Inhibitors Topic Review
Proprotein convertase subtilisin/kexin type 9 (PCSK9) is a protein that binds to the LDL receptor on hepatocytes, promoting its internalization and degradation within the cell. [Repatha package insert;9a]